David C. Blakey
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Enhancing SIRT1 Gene Expression Using Small Activating RNAs: A Novel Approach for Reversing Metabolic Syndrome.
Journal: Nucleic acid therapeutics
Published: July 27, 2022
MTL-CEBPA Combined with Immunotherapy or RFA Enhances Immunological Anti-Tumor Response in Preclinical Models.
Journal: International journal of molecular sciences
Published: July 25, 2021
Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug.
Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: May 07, 2020
MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 31, 2020
Anti-inflammatory Activity of MTL-CEBPA, a Small Activating RNA Drug, in LPS-Stimulated Monocytes and Humanized Mice.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: November 29, 2018
Development and Mechanism of Small Activating RNA Targeting CEBPA, a Novel Therapeutic in Clinical Trials for Liver Cancer.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: February 23, 2017
Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.
Journal: Science translational medicine
Published: December 07, 2016
AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer.
Journal: Science translational medicine
Published: November 20, 2015
Identification of novel vascular targets in lung cancer.
Journal: British journal of cancer
Published: November 13, 2014
Novel neutralizing hedgehog antibody MEDI-5304 exhibits antitumor activity by inhibiting paracrine hedgehog signaling.
Journal: Molecular cancer therapeutics
Published: December 18, 2013
Inhibition of platelet-derived growth factor receptor α by MEDI-575 reduces tumor growth and stromal fibroblast content in a model of non-small cell lung cancer.
Journal: Molecular pharmacology
Published: April 06, 2013
Last Updated: 09/26/2026